| Antimicrobial Agent | Susceptibility Profile | Clinical Interpretation |
|---|---|---|
| Amikacin | Resistant | >=64 |
| Cefepime | Resistant | >=64 |
| Cefotaxime | Resistant | 256 |
| Ceftazidime | Resistant | >=64 |
| Ceftriaxone | Resistant | >256 |
| Ciprofloxacin | Resistant | >=4 |
| Colistin | Intermediate | <0.125 |
| Doripenem | Resistant | >=8 |
| Gentamicin | Resistant | >=16 |
| Imipenem | Resistant | >=16 |
| Levofloxacin | Sensitive | >=8 |
| Meropenem | Resistant | >=16 |
| Minocycline | Sensitive | 4 |
| Piperacillin/Tazobactam | Resistant | >=128 |
| Ticarcillin-clavulanic acid | Resistant | >=128 |
| Tobramycin | Resistant | >256 |
| Trimethoprim/Sulfamethoxazole | Resistant | >=320 |
| Resistant Gene Track | Detection Methodology | NCBI Genome Accession |
|---|---|---|
| blaoxa51-like | PCR |